Teladoc Health R&D Spending Growth & History (TDOC)
Teladoc Health's r&d spending was $277.9M for fiscal 2025.
View full Teladoc Health company overviewTeladoc Health annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $277.9M | −$29.4M | −9.55% |
| 2024 | 2024-12-31 | $307.3M | −$41.2M | −11.83% |
| 2023 | 2023-12-31 | $348.5M | $14.9M | +4.46% |
| 2022 | 2022-12-31 | $333.6M | $21.7M | +6.97% |
| 2021 | 2021-12-31 | $311.9M | $146.9M | +89.09% |
| 2020 | 2020-12-31 | $164.9M | $100.3M | +155.15% |
| 2019 | 2019-12-31 | $64.6M | $10.3M | +18.89% |
| 2018 | 2018-12-31 | $54.4M | $19.9M | +57.79% |
| 2017 | 2017-12-31 | $34.5M | $12.6M | +57.96% |
| 2016 | 2016-12-31 | $21.8M | $7.6M | +53.52% |
| 2015 | 2015-12-31 | $14.2M | $6.6M | +87.64% |
| 2014 | 2014-12-31 | $7.6M | $4.0M | +114.41% |
| 2013 | 2013-12-31 | $3.5M | — | — |
Teladoc Health quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $62.9M | −$5.9M | −8.61% |
| Q1 2026 | 2026-03-31 | $67.9M | −$2.1M | −2.99% |
| Q4 2025 | 2025-12-31 | $71.6M | −$5.1M | −6.70% |
| Q3 2025 | 2025-09-30 | $67.6M | −$4.8M | −6.65% |
| Q2 2025 | 2025-06-30 | $68.8M | −$8.0M | −10.38% |
| Q1 2025 | 2025-03-31 | $70.0M | −$11.4M | −14.04% |
| Q4 2024 | 2024-12-31 | $76.8M | −$13.2M | −14.66% |
| Q3 2024 | 2024-09-30 | $72.4M | −$11.9M | −14.13% |
| Q2 2024 | 2024-06-30 | $76.8M | −$10.6M | −12.09% |
| Q1 2024 | 2024-03-31 | $81.4M | −$5.6M | −6.43% |
| Q4 2023 | 2023-12-31 | $89.9M | $7.0M | +8.45% |
| Q3 2023 | 2023-09-30 | $84.3M | −$301,000 | −0.36% |
| Q2 2023 | 2023-06-30 | $87.3M | $8.6M | +10.94% |
| Q1 2023 | 2023-03-31 | $87.0M | −$427,000 | −0.49% |
| Q4 2022 | 2022-12-31 | $82.9M | $10.1M | +13.81% |
| Q3 2022 | 2022-09-30 | $84.6M | $4.3M | +5.41% |
| Q2 2022 | 2022-06-30 | $78.7M | −$2.1M | −2.55% |
| Q1 2022 | 2022-03-31 | $87.4M | $9.4M | +12.06% |
| Q4 2021 | 2021-12-31 | $72.9M | −$19.8M | −21.39% |
| Q3 2021 | 2021-09-30 | $80.3M | $50.3M | +167.88% |
| Q2 2021 | 2021-06-30 | $80.8M | $57.7M | +250.68% |
| Q1 2021 | 2021-03-31 | $78.0M | $58.8M | +305.09% |
| Q4 2020 | 2020-12-31 | $92.7M | $76.5M | +470.58% |
| Q3 2020 | 2020-09-30 | $30.0M | $14.2M | +90.26% |
| Q2 2020 | 2020-06-30 | $23.0M | $6.4M | +38.19% |
| Q1 2020 | 2020-03-31 | $19.3M | $3.3M | +20.45% |
| Q4 2019 | 2019-12-31 | $16.2M | $2.7M | +19.95% |
| Q3 2019 | 2019-09-30 | $15.7M | $2.2M | +15.98% |
| Q2 2019 | 2019-06-30 | $16.7M | $2.3M | +16.15% |
| Q1 2019 | 2019-03-31 | $16.0M | $3.1M | +23.89% |
| Q4 2018 | 2018-12-31 | $13.5M | $3.1M | +29.66% |
| Q3 2018 | 2018-09-30 | $13.6M | $3.6M | +36.26% |
| Q2 2018 | 2018-06-30 | $14.3M | $6.8M | +90.37% |
| Q1 2018 | 2018-03-31 | $12.9M | $6.4M | +98.16% |
| Q4 2017 | 2017-12-31 | $10.4M | $4.6M | +77.23% |
| Q3 2017 | 2017-09-30 | $10.0M | $4.1M | +69.83% |
| Q2 2017 | 2017-06-30 | $7.5M | $2.7M | +56.08% |
| Q1 2017 | 2017-03-31 | $6.5M | $1.3M | +24.63% |
| Q4 2016 | 2016-12-31 | $5.9M | $1.7M | +41.68% |
| Q3 2016 | 2016-09-30 | $5.9M | $1.9M | +48.87% |
| Q2 2016 | 2016-06-30 | $4.8M | $1.6M | +50.76% |
| Q1 2016 | 2016-03-31 | $5.2M | $2.3M | +79.80% |
| Q4 2015 | 2015-12-31 | $4.2M | — | — |
| Q3 2015 | 2015-09-30 | $3.9M | $2.0M | +101.07% |
| Q2 2015 | 2015-06-30 | $3.2M | $1.1M | +55.18% |
| Q1 2015 | 2015-03-31 | $2.9M | — | — |
| Q3 2014 | 2014-09-30 | $2.0M | — | — |
| Q2 2014 | 2014-06-30 | $2.1M | — | — |
Teladoc Health r&d spending trends
Over the last five fiscal years, Teladoc Health's r&d spending increased from $164.9M to $277.9M, a change of $113.0M. The latest reported quarter, Q2 2026, shows $62.9M.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Teladoc Health source filings ↗